122
Participants
Start Date
October 16, 2020
Primary Completion Date
March 11, 2022
Study Completion Date
May 4, 2022
IMR-687
Oral administration of once daily IMR-687
Placebo
Oral administration of once daily Placebo
Chronic Care Center, Hazmiyeh
Centre National de Greffe de la Moelle Osseuse, Tunis
Hospital Aziza Othmana, Tunis
Herlev Hospital, Herlev
Centre Hôpital Universitaire Farhat Hached, Sousse
Azienda Ospedaliera Giuseppe Brotzu, Orbassano
Azienda Ospedaliera Universitaria - Università degli Studi della Campania Luigi Vanvitelli, Orbassano
Hôpital d'Enfants Rabat, Rabat
Hospital Pulau Pinang, George Town
Aghia Sofia General Children's Hospital, Athens
Laiko General Hospital of Athens, Athens
Emek Medical Center, Afula
University General Hospital of Patras, Patra
Hospital Raja Permaisuri Bainun, Ipoh
Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse
Akdeniz Üniversitesi, Mersin
Mersin Üniversitesi Tıp Fakültesi, Mersin
Ege Universitesi Tip Fakultesi, Izmir
Ippokrateio General Hospital of Thessaloniki, Thessaloniki
Hôpital Edouard Herriot, Lyon
Hôpital Necker-Enfants Malades, Paris
Hospital Sultanah Aminah Johor Bharu, Johor Bahru
Hospital Queen Elizabeth - Kota Kinabalu, Kota Kinabalu
Hospital Umum Sarawak, Kuching
The Galilee Medical Center, Nahariya
Rambam Health Care Campus, Haifa
Hadassah University Hospital Ein Kerem, Jerusalem
M. Zodelava Hematology Centre, Tbilisi
National Center of Surgery, Tbilisi
Medinvest - Institute of Hematology and Transfusiology, Tbilisi
Hospital Sultanah Bahiyah, Alor Star
Amsterdam Universitair Medische Centra - Academisch Medisch Centrum, Amsterdam
Hacettepe Üniversitesi, Ankara
Whittington Health NHS Trust, London
University College London Hospitals NHS Foundation Trust, London
Manchester University NHS Foundation Trust, Manchester
Lead Sponsor
Imara, Inc.
INDUSTRY
Cardurion Pharmaceuticals, Inc.
INDUSTRY